Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-991 in metastatic hormone-sensitive prostate cancer
2019-003633-41Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Pembrolizumab + enzalutamide + ADT with Placebo + enzalutamide + ADT (2 arms). Primary endpoint: Radiographic progression-free survival. Started Dec 2019; status: completed.
02
Drugs
pembrolizumabenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2019-003633-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003633-41.